Clinical trials: Dialysis-Dependent Chronic Kidney Disease
Chronic Kidney Disease, Anemia
Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Anemia of inflammation is a common complication in patients with chronic kidney disease (CKD). Patients with CKD and anemia of inflammation also exhibit decreased response to erythropoietic agents, even in the presence of…
- Trial name
- NCT00609544
- Testing
- Rilonacept
- Where
- 27 sites in United States
- Sponsor
- Regeneron Pharmaceuticals
Anemia Due to Chronic Kidney Disease
A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia
This is a phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in anemic patients with End-Stage-Kidney-Disease (ESKD)
- Trial name
- NCT07494409
- Testing
- AND017 capsules, ESA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Kind Pharmaceuticals LLC
Iron Deficiency Anemia
A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease
Study AMAG-FER-CKD-253 is an extension study of the combined AMAG-FER-CKD-251 (NCT01155375) and AMAG-FER-CKD-252 (NCT01155388) studies to evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with…
- Trial name
- NCT01264679
- Testing
- Ferumoxytol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Chronic Kidney Disease
Evolution of Bone Histomorphometry and Vascular Calcification Before and After Renal Transplantation
A study of the natural history of bone and mineral disease (BMD) in patients with end-stage renal disease before and after kidney transplantation
- Trial name
- NCT01886950
- Where
- Belgium
- Volunteers
- 250 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Anaemia
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)
This Phase 3 study in hemodialysis-dependent subjects with anemia will evaluate the efficacy and safety of daprodustat administered three-times weekly compared to epoetin alfa, the current standard of care.
- Trial name
- NCT03400033
- Testing
- Daprodustat tablets, Epoetin alfa vials, Saline vials or bags
- Where
- 91 sites in United States, Argentina and 11 more
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease, Hemodialysis
L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD
Cardiovascular disease is the primary cause of death in patients with end stage renal disease (ESRD). New research suggests that the high risk of death may be partly due to high levels of fibrosis and a loss of small blood…
- Trial name
- LAST-D (NCT01855334)
- Testing
- Spironolactone, L-arginine
- Where
- 3 sites in United States
- Sponsor
- Brigham and Women's Hospital
Non-dialysis Dependent Chronic Kidney Disease
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKD
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer® in patients suffering from Non-dialysis Dependent Chronic Kidney Disease.
- Trial name
- PK-CKD-03 (NCT01213992)
- Testing
- Iron isomaltoside 1000
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Anaemia
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable rhEPO to GSK1278863 in approximately 68…
- Trial name
- NCT01587924
- Testing
- GSK1278863, rhEPO
- Where
- 62 sites in United States, Canada and 4 more
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Iron Deficiency Anaemia, Chronic Kidney Disease
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron…
- Trial name
- FIND-CKD (NCT00994318)
- Testing
- FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
- Where
- 19 sites in United States, Australia and 17 more
- Volunteers
- 626 people
- Sponsor
- Vifor Pharma
Iron Deficiency, Anaemia
Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)
Investigation whether a switch from oral iron to intravenous ferric carboxymaltose can reduce dose requirements of erythropoiesis-stimulating agents (ESA) and improve Hb levels and iron status in adult patients with…
- Trial name
- NCT02232906
- Testing
- intravenous ferric carboxymaltose
- Where
- Argentina
- Volunteers
- 30 people
- Sponsor
- Hospital Aleman
Chronic Kidney Diseases, Iron Deficiency Anemia
KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)
The objectives of this study are to assess the long-term efficacy and safety of different dose regimens of KRX-0502 in the treatment of iron deficiency anemia (IDA) in adult subjects with non-dialysis dependent chronic kidney…
- Trial name
- COMPASS (NCT03236246)
- Testing
- KRX-0502
- Where
- 28 sites in United States
- Volunteers
- 206 people
- Sponsor
- Keryx Biopharmaceuticals
Kidney Failure, Chronic, Hepatitis C
Safety of Sofosbuvir in People With Advanced Kidney Failure
Infection with hepatitis C virus (HCV), a hepatotropic RNA virus, is often chronic, and causes liver cirrhosis and liver cancer. The virus is transmitted through parenteral exposure.
- Trial name
- NCT03883698
- Testing
- Sofosbuvir, Daclatasvir 60 mg
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Anemia
Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients
The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.
- Trial name
- NCT00255424
- Testing
- ferumoxytol or oral iron
- Where
- 19 sites in United States
- Volunteers
- 304 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Secondary Hyperparathyroidism, Chronic Kidney Disease Mineral and Bone Disorder
Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients
This is a prospective cohort study aimed to evaluate change of cardiovascular calcification after parathyroidectomy in patients with end-stage renal disease on dialysis compared with control group on conservative treatment.
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease Mineral and Bone Disorder, Vascular Calcification, Dialysis
- Trial name
- NCT03937349
- Where
- Russia
- Volunteers
- 63 people
- Sponsor
- Saint Petersburg State University, Russia
Chronic Kidney Disease Associated Anemia
Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease
The CANNON trial is a prospective, open-label, randomized, multicenter study designed to investigate rational hemoglobin target value in patients with anemia of non-dialysis chronic kidney disease treated with enarodustat.
- Trial name
- CANNON (NCT06725810)
- Testing
- Enarodustat
- Where
- China
- Volunteers
- 1,670 people
- Sponsor
- Shanghai Zhongshan Hospital
Anemia, Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
- Trial name
- NCT02865850
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 118 sites in United States, Argentina and 9 more
- Volunteers
- 369 people
- Sponsor
- Akebia Therapeutics
Renal Anemia
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients
- Trial name
- NCT05035641
- Testing
- AND017
- Where
- 8 sites in United States, China
- Volunteers
- 113 people
- Sponsor
- Kind Pharmaceuticals LLC
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure
Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector, outcomes assessor), placebo-controlled trial.
- Conditions
- Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
- Trial name
- TRACK (NCT03969953)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- 88 sites in Australia, Belgium and 10 more
- Volunteers
- 1,753 people
- Sponsor
- The George Institute
Chronic Kidney Disease, Anemia
Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
This is a Phase 1b, randomized, double-blinded, placebo-controlled study of CTX001 in participants with anemia and chronic kidney disease who are not on dialysis.
- Trial name
- NCT07901933
- Testing
- CTX001, Ferrous Sulfate
- Where
- 4 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Cajal Therapeutics Inc.
End-stage Kidney Disease, Kidney Disease, Chronic
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients.
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic
- Trial name
- NCT05614115
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Utah